Latest Virus-like particle Stories
RALEIGH, North Carolina and QUEBEC CITY, Quebec, Nov. 10, 2011 /PRNewswire/ - Medicago U.S.A. Inc., a wholly owned subsidiary of Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that company executives, along with North Carolina Governor Beverly Perdue, U.S. Senator Richard Burr and Congressman David Price, are holding an...
QUEBEC CITY, Nov. 9, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Mr. Pierre Labbe, the Company's Chief Financial Officer, has been invited to present at the Lazard Capital Markets 8th Annual Healthcare Conference. The conference will be held at The Pierre Hotel in New York City on November...
- Receives Approval to Proceed to Second Stage of Agreement - QUEBEC CITY, Oct. 12, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the successful completion of the first stage of its research collaboration, announced initially on April 6, 2011, with a top 10 global pharmaceutical company for the...
ATLANTA, Oct. 3, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today the completion of enrollment for a Phase 2a clinical trial testing its HIV/AIDS vaccine. The vaccine is being developed for use in uninfected people to prevent infection should they be exposed to the virus. The trial, designated HVTN 205, is being conducted by the HIV...
-Operations begin within eleven months of hosting groundbreaking ceremony- RALEIGH, NC and Quebec City, Sept. 13, 2011 /PRNewswire/ - Medicago USA Inc., a wholly owned subsidiary of Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has commenced operations at its 97,000-square-foot plant-based vaccine facility in...
- all three standard antibody tests confirm the strong immunogenicity of Medicago's H5N1 and H1N1 VLP vaccine candidates - QUEBEC CITY, Sept. 12, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Dr. Brian Ward will be presenting clinical data at the Fourth ESWI Influenza Conference, Malta 2011....
-Prestigious recognition for Medicago's VLP vaccine technology platform- QUEBEC CITY, Aug. 23, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has won the 2011 Frost & Sullivan Enabling Technology of the Year award in the vaccine market. This award recognizes Medicago's achievements and...
QUEBEC CITY, QC, Aug. 12, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced its operational and financial results for the second quarter ended June 30, 2011. The Company's financial statements and management report are available at www.sedar.com and at www.medicago.com. "During the second quarter, we...
- Phase II part B confirms results obtained in Phase II part A - - Company's results continue to be amongst the best for influenza vaccine manufacturing technologies - QUEBEC CITY, June 30, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive final results from a Phase II human clinical trial...
- 2011 "Prix Santé" presented by the Armand-Frappier Foundation - - 2011 Genesis Entrepreneurship Award presented by BIOQuebec - QUEBEC CITY, June 22, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announced today that it was named this month both the recipient of the 2011 "Prix Santé" awarded by the...
